As if those of us in the know weren’t already fully aware, however, a new study shows that compounds found in marijuana known as cannabinoids are a safe, “modestly” effectual treatment for the management of chronic non-cancer pain.
Although the scientific research in the United States regarding the medicinal attributes of marijuana is currently insubstantial at best, Canada has upped their levels of examination.
Researchers from Dalhousie University, Halifax, Canada, and the Hospital for Sick Children, University of Toronto, Toronto, Canada conducted the aforementioned study that was published in the Journal of Neuroimmune Pharmacology, which involved a systematic review of 11 placebo-controlled trials conducted from 2010 and 2014 exploring cannabinoids and chronic pain.
The cannabinoids involved in said study included smoked marijuana, oromucosal extracts of cannabis based medicine, nabilone, dronabinol and an unconventional THC analogue.
The research team concluded that the quality of the trials that they conducted were “excellent”, and that seven out of the eleven trials “demonstrated a significant analgesic effect.”
Furthermore, it was disclosed that several of the trials also “demonstrated improvement in secondary outcomes (e.g., sleep, muscle stiffness and spasticity)”, and that unfavorable effects which were most frequently reported “such as fatigue and dizziness were mild to moderate in severity and generally well tolerated.”
Here’s what the study’s authors wrote:
We conclude that it is reasonable to consider cannabinoids as a treatment option in the management of chronic neuropathic pain with evidence of efficacy in other types of chronic pain such as fibromyalgia and rheumatoid arthritis as well.